Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong short-term momentum backed by a recent operating catalyst: on 2026-05-06 the company raised full-year 2026 guidance for revenue, medical margin, and adjusted EBITDA, while the stock gained about 55% over 21 trading days and continued closing near the top of its range.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Full reversal ⢠Lower highs ⢠Key support Support Level: $98.00-$100.00 Resistance Level: $115.00-$116.00 AGL surged to 129.84 in the last month but has since fully reversed to 98.00, shifting the short-term trend bearish with 98-100 as key support and 115-116 now resistance.
Sentiment & News
Key News Insights: ⢠Valuation momentum ⢠Strong savings results ⢠Legal scrutiny Agilon Health has combined modest stock momentum and strong ACO REACH savings results with fresh legal scrutiny, leaving the upcoming Aug. 5 earnings report as the key near-term catalyst.
AI Summary
AGL is now a âshow meâ investment: the FY26 guidance lift from better plant availability and retail margins is credible, but recurring outage risk and rising decarbonization costs are turning the stock into a test of whether operational gains can outrun a heavier structural earnings drag.
Description
agilon health, inc. provides healthcare services for senior patients through primary care physicians in communities across the United States. As of December 31, 2021, the company served about 238,000 senior members, including 186,300 Medicare Advantage members and 51,700 Medicare fee-for-service beneficiaries. Founded in 2016 and based in Austin, Texas, the company adopted its current name in March 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 10 | Jun 17 | AGL | Agilon Health, Inc. | Strong short-term momentum backed by a recent operating catalyst: on 2026-05-06 the company raised full-year 2026 guidance for revenue, medical margin, and adjusted EBITDA, while the stock gained about 55% over 21 trading days and continued closing near the top of its range. | Closed | +2.9% |
| May 21 | May 28 | AGL | Agilon Health, Inc. | High-risk but clear short-term momentum catalyst: 2026-05-06 Q1 update beat estimates and raised full-year 2026 guidance for revenue, medical margin, and adjusted EBITDA. Stock surged sharply after earnings and is up about 206% over 21 trading days. | Closed | +12.2% |